Semaglutide Guide & Protocols

Semaglutide is the compound that put GLP-1 research on the map, and it's still the one most people compare everything else against. Below is the weekly titration pattern most commonly described for research-grade semaglutide, how it's cycled and stacked, and how it compares to tirzepatide if you're weighing the two.

Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target dose you're working with.

What it is

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a gut hormone that stimulates insulin release, slows digestion, and signals the brain that you've had enough to eat. The research version is sold as a lyophilized powder, the same molecule found in the approved drugs Ozempic, Wegovy, and Rybelsus, but manufactured and sold outside pharmaceutical channels as a research chemical. It isn't approved or regulated as sold by research vendors, and purity and concentration accuracy vary by source, which is a bigger deal here than with most compounds on this site given how widely it's counterfeited.

What people use it for

Semaglutide is one of the two GLP-1 weight-loss peptides most people land on first, tirzepatide is the other, and weight and appetite regulation is almost the entire conversation here, mirroring the approved drug's own indication. The appeal of the research-grade version is straightforward. It's the same molecule at a fraction of the pharmacy price, dosed by mg from a vial instead of a fixed-increment pen. A smaller but real thread of interest sits in metabolic markers more broadly, blood sugar, triglycerides, and blood pressure, since those tend to move alongside the weight change.

Formulations

Semaglutide ships as a lyophilized powder that needs reconstitution before use. Vendors most commonly sell 2, 5, and 10 mg vials. There's no research-grade oral version, so the injectable route is what circulates, even though the approved pharmaceutical line also includes an oral tablet (Rybelsus) that isn't something research vendors replicate.

Dosing protocols

Unlike most compounds on this site, semaglutide's weekly amounts trace to a real, publicly documented source: the titration schedule built into the approved drug's own prescribing information. Research-grade dosing commonly mirrors it directly, expressed in mg instead of the pen's fixed increments.

See the Semaglutide research notes for more background before reading the dosing itself.

Standard titration

The pattern most closely mirroring the approved titration schedule. Weeks 1 to 4: 0.25 mg weekly. Weeks 5 to 8: 0.5 mg weekly. Weeks 9 to 12: 1 mg weekly. Weeks 13 to 16: 1.7 mg weekly. Week 17 onward: 2.4 mg weekly, held as the maintenance amount.

Slower titration

A gentler, less commonly used variant. The same step sequence above, held for 6 to 8 weeks per step instead of 4, reaching maintenance later. Commonly described as easier to tolerate through the early weeks, at the cost of a longer runway to the full weekly amount.

Amount total, for planning your vial purchase: the first 16 weeks of standard titration add up to 13.8 mg (1 mg across weeks 1 to 4, plus 2 mg across weeks 5 to 8, plus 4 mg across weeks 9 to 12, plus 6.8 mg across weeks 13 to 16). A year of maintenance at 2.4 mg weekly for the remaining 36 weeks adds another 86.4 mg, for a first-year total of roughly 100 mg. Every year after that, held at maintenance, runs closer to 125 mg (2.4 mg times 52 weeks). Compare vendors on price per milligram against that total rather than against the price of a single vial.

How much to reconstitute at once: a reconstituted vial is generally good for about 28 days refrigerated, so the amount to mix at one time is whatever four weeks of the current step actually uses, not the whole vial. Early in titration, four weeks at 0.25 to 0.5 mg weekly only draws 1 to 2 mg, so reconstituting a full 10 mg vial that early leaves most of it wasted once the 28-day window closes. Once the 2.4 mg maintenance amount is reached, four weeks draws 9.6 mg, which lines up closely with a single 10 mg vial. See how much to reconstitute at once for the general math.

Cycling guidelines

Semaglutide doesn't have a defined on-then-off cycling convention. What's described instead is a single titration to a maintenance weekly amount, continued for as long as someone is actively pursuing the effect, commonly discussed in stretches of a year or more rather than a matter of weeks. The trial record backs this up: the SURMOUNT and STEP programs both point to weight regain once treatment stops, which is the main reason people describe this as an ongoing commitment rather than a short course.

Where stopping comes up, it's more often described as a gradual step down in weekly amount rather than an abrupt stop, though we found no source establishing a specific taper schedule.

Signs a course is commonly stopped or reconsidered:

• Severe or persistent abdominal pain, particularly if it radiates to the back
• Signs of a gallbladder problem, such as pain in the upper right abdomen or yellowing of the skin or eyes
• Digestive symptoms severe enough to affect eating or hydration day to day
• Vision changes, which is one of the newer signals researchers are watching in people with existing diabetic eye disease

Stacking

Most commonly paired stack: Semaglutide with CJC-1295 and Ipamorelin.

Rationale: the growth hormone pair is discussed specifically for preserving lean mass and sleep quality during a sustained calorie deficit, which is exactly what a semaglutide course tends to create.

Protocol as run: CJC-1295 (commonly the no-DAC, faster-clearing version when paired with Ipamorelin) and Ipamorelin dosed daily, most often before sleep, run alongside semaglutide's weekly schedule rather than matched to it.

Why it's paired: the two are addressing different problems. Semaglutide is working at the appetite and receptor level; the GH pair is aimed at what a hard, sustained deficit tends to cost you, mainly muscle.

Lighter stacks: BPC-157 shows up as a gut-support pairing, since digestive side effects are the most common complaint early in a semaglutide course. MOTS-c shows up as a cellular-energy pairing, addressing fuel efficiency at the mitochondrial level rather than the appetite level semaglutide works through. Both are rationale plus a loosely matched schedule, not protocols with any dedicated combination data.

Combinations to approach carefully: tirzepatide and retatrutide both come up, usually from someone weighing whether to switch rather than run two GLP-1 pathway compounds side by side. Running two compounds that work through the same or overlapping receptor pathways at once isn't something we found a rationale or a safety precedent for anywhere, and it isn't the same conversation as switching from one to the other.

Expected results timeline

Early weeks: this is mostly an adjustment period during titration. Digestive symptoms are the most noticeable thing during this stretch, especially right after each step up, and appetite changes are usually apparent well before any real weight change is.

Months in: once maintenance is reached, this is where the effects most people are tracking for start showing up, appetite, weight, and the metabolic markers that move alongside it. The STEP 1 trial's 14.9% mean weight reduction was measured over 68 weeks, so the timeline the trial data actually supports is closer to a year and a half than a few months.

Extended, continued use: the largest cumulative changes are described as building over many months to well over a year of sustained maintenance dosing, not something that shows up quickly.

What to expect realistically: the STEP 1 average of a 14.9% reduction is a mean across a large trial population, and averages hide a wide spread between individuals. The same trial found placebo-group participants regained weight when treatment stopped, which is the clearest evidence that this is describing an ongoing effect tied to continued dosing, not a one-time reset.

Administration technique

1. The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target weekly amount.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
3. The calculated volume is drawn into an insulin syringe or similar fine-gauge syringe.
4. A subcutaneous site is chosen, commonly the abdomen or the front of the thigh, with sites rotated week to week.
5. The skin is pinched and the injection given at roughly a 45-degree angle, held for a few seconds before withdrawal.
6. Each weekly injection is commonly logged by date, amount, and site, which matters more here than for a short course, since a titration schedule runs across several months before maintenance is even reached.

Side effects and safety

Common: nausea is the most consistently reported effect, and it climbs with weekly amount, most noticeable right after a step up in the titration schedule. Diarrhea, constipation, and vomiting follow a similar pattern.

Less common: pancreatitis is a rare but recognized concern flagged in the prescribing information. Gallbladder problems, including gallstones, are reported more often in people losing weight quickly, which is a class-level effect of significant weight loss itself rather than something specific to the mechanism.

Stopping due to side effects: people leaving a course because the digestive effects are hard to tolerate becomes more common at higher weekly amounts, which is part of why the titration schedule steps up gradually instead of starting at the maintenance amount.

What we don't know: thyroid C-cell tumors were observed in rodent studies at doses well above the human range, and whether that finding is relevant to people is still being studied; it's the reason the approved product carries a boxed warning and a personal or family history of certain thyroid cancers is listed as a contraindication. Long-run outcomes in people using research-grade material outside clinical supervision aren't tracked anywhere, so treat anything beyond the trial window as an open question.

Contraindications: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a personal history of pancreatitis, are the two most consistently cited. Pregnancy, breastfeeding, and use in minors all have no research-grade safety data behind them and should be avoided.

Drug interactions: because this class of compound slows how quickly the stomach empties, it can affect how quickly anything else taken by mouth around the same time gets absorbed, including other medications with a narrow effective range. That's flagged in the prescribing information for the approved product and is reasonable to expect for research-grade material too.

Semaglutide vs. Tirzepatide

If you're weighing semaglutide against something else, tirzepatide is the compound people actually cross-shop it against, since it's the other GLP-1-class compound with its own approved pharmaceutical line and the deepest trial record after semaglutide's own.

Choose semaglutide if: the longest trial history and the deepest cardiovascular outcome data in this category, from the SUSTAIN-6 and SELECT trials, matter most to you.

Choose tirzepatide if: the larger average trial weight reduction is the priority and you're comfortable with a shorter overall trial history.

See the Tirzepatide research notes for its own trial data, mechanism, and pricing.

Storage and handling

Lyophilized powder: refrigerate at 2 to 8°C for near-term use. Kept frozen instead, the unreconstituted powder is commonly described as stable for considerably longer. Protect from light. Lot-specific stability should come from the vendor's certificate of analysis, not a general rule.

Reconstituted solution: refrigerate, and plan to use it within the window your vendor specifies, generally within 28 days once water has been added. That 28-day figure comes from the same compounding-pharmacy standard used industry-wide for a bacteriostatic-water solution, not from the approved pharmaceutical pen. The pen carries its own, longer, 56-day in-use window, but that figure belongs to a sealed, single-access-per-dose device with its own tested formulation, not a vial that gets punctured repeatedly at home, so it isn't a fair number to borrow. See how much to reconstitute at once before buying a larger vial than the 28-day window can realistically use. Avoid repeated freeze-thaw cycles.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• Discoloration of the powder or reconstituted liquid
• A previously reliable appetite effect that unexpectedly stops showing up at an unchanged weekly amount, though this is a soft signal at best

FAQ

Semaglutide or tirzepatide, which one do I actually want? If the longest trial history and the deepest cardiovascular data matter most, semaglutide. If the larger average trial weight reduction is the priority, tirzepatide.

How is it typically titrated? Most commonly starting at 0.25 mg weekly and stepping up roughly every 4 weeks toward a 2.4 mg maintenance amount, mirroring the approved drug's own titration schedule.

How long do people run it? Commonly a year or more at a maintained weekly amount, rather than a short, defined course, since the trial data shows weight regain once dosing stops.

Can I take it orally? Research vendors don't sell an oral version. What circulates is injectable, even though an oral pharmaceutical tablet (Rybelsus) exists by prescription.

Is it safe to combine with the GH pair, CJC-1295 and Ipamorelin? No dedicated combination data exists. People run them together based on the different problems each addresses, not on tested safety.

Does the weekly amount affect side effects? Yes, digestive side effects track upward with weekly amount, which is why titration steps up gradually instead of starting at the maintenance dose.

Is there a thyroid or pancreatitis risk? The same caution used across this class of compound applies to semaglutide directly, since it's the compound the boxed warning was written for. See Side effects and safety above.

How is it stored? Refrigerated as a powder, refrigerated and used within about 28 days once reconstituted.

What's the difference between the vial sizes? Only the concentration and how many vials your weekly schedule requires over time; 2, 5, and 10 mg are the common sizes, and the reconstitution calculator handles the arithmetic either way.

Bottom line

Key dosing takeaways:

• Titrating from 0.25 mg weekly up to a 2.4 mg maintenance amount over 16 weeks, mirroring the approved drug's own schedule, is the pattern people actually run
• That titration traces directly to real prescribing information rather than forum consensus, which is rare on this site and worth knowing when comparing it to compounds with no traceable dosing origin
• Digestive side effects climb with weekly amount, which is the whole reason the titration steps up gradually instead of starting at maintenance

Best practices:

• Comparing vendors by total milligrams over a realistic multi-month titration and a year of maintenance, not by vial count, is where the real price differences show up
• Logging each weekly injection keeps a maintained schedule from relying on memory over many months
• Watching for the same warning signs the approved product's label flags, especially around the gallbladder and pancreas, applies just as much to research-grade material

Works best for people who:

• Want the compound with the longest trial history and the deepest cardiovascular outcome data in this category
• Are prepared for an ongoing, months-to-years commitment rather than a short course
• Can tolerate, or are prepared to manage, dose-dependent digestive side effects during titration